National Institutes of Health Awards Moonlight Therapeutics with a $2.5 Million Grant to Advance Development of Peanut Allergy Treatment
Tuesday, May 07, 2019 03:50 PM

Funding to support company’s preclinical development of a breakthrough allergy treatment

Moonlight Therapeutics, Inc., a biotechnology company developing treatments for food allergies, announced today the receipt of $2.5 million in funding for preclinical studies and product development that will enable preparations for a clinical trial for its lead program in peanut allergy. This funding was awarded through a highly competitive Small Business Technology Transfer (STTR) Fast Track grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

Moonlight’s proprietary platform, TASIS — Targeted Allergen-Specific Immunotherapy within the Skin — involves the application of a small, minimally invasive dermal stamp that uses microneedles to target the delivery of allergens to the skin’s immune cells. The stamp is removed within a few minutes and the administration is complete.

Emory plans $475M cancer tower at Emory University Hospital Midtown
Monday, May 06, 2019 05:44 PM

Emory University is planning a $475 million cancer tower at Emory University Hospital Midtown.

The new cancer tower at 550 Peachtree Street would be 17 stories and be located on the north side of the EUHM campus and connected to the existing hospital, according to plans filed with the Georgia Department of Community Health.

The tower will consist of approximately 455,000 square feet of new construction and will include about 64 inpatient beds and 26 observation beds. "The tower will also include research space, perioperative services, imaging services, radiation oncology, a clinical laboratory, pharmacy, infusion therapy and outpatient clinic space. In addition, an array of support services will located in the new tower," Emory says.

Skyhawk signs neuro deal with Takeda as it prepares to expand its partnered indications
Monday, May 06, 2019 12:00 AM

Skyhawk signed its third major deal in a year, this time with Takeda. Like its first two partnerships, the focus will be in neurology, but Skyhawk is in discussions with companies that could help extend its platform to other areas.

On Tuesday, Skyhawk Therapeutics Inc. (Waltham, Mass.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exclusive worldwide rights to therapies against multiple targets for undisclosed neurodegenerative diseases. Skyhawk will be responsible for discovery and preclinical development using its SkySTAR platform, after which Takeda will take over the programs. Financial details are undisclosed.

Emory files plans for $1 billion Executive Park campus
Friday, May 03, 2019 02:52 PM

Emory University plans a $1 billion, 15-year-plus development of a new "health innovation district" on North Druid Hills Road at Interstate 85.

In 2016, Emory bought about 60 acres in Executive Park, directly across North Druid Hills Road from where Children's Healthcare of Atlanta is now developing a $1.5 billion hospital campus

On May 1, Emory filed a rezoning application with the city of Brookhaven in which it envisions a mixed-use development on the property with office, medical services, a hospital, commercial space, a hotel and multifamily. Emory says it seeks to replace the retail and office developments now on the property with a development "that builds on the successful programs in orthopedics, sports medicine, brain health, medical science education and health information technology already located on the site."

Takeda Inks Licensing Option Agreement with Gene Editing Platform Developer Emendo
Wednesday, April 24, 2019 12:00 AM

Takeda Pharmaceutical has advanced further into gene editing, inking a licensing option agreement with and, through its venture capital arm, investing in Emendo Biotherapeutics, the gene editing discovery platform developer said today.

The value of the agreement and the investment were not disclosed.

Through the licensing option agreement, Emendo has granted Takeda the option to use its proprietary nuclease program OMNI to edit two genes as part of the pharma’s R&D efforts to treat unspecified genetic disorders.

<< first < Prev 1 2 3 4 5 6 7 8 9 10 Next > last >>

Page 5 of 49